Matthew Reynolds to Gene Products, nef
This is a "connection" page, showing publications Matthew Reynolds has written about Gene Products, nef.
Connection Strength
0.197
-
Reynolds MR, Weiler AM, Piaskowski SM, Piatak M, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine. 2012 Jun 22; 30(30):4465-75.
Score: 0.096
-
Burwitz BJ, Ende Z, Sudolcan B, Reynolds MR, Greene JM, Bimber BN, Almeida JR, Kurniawan M, Venturi V, Gostick E, Wiseman RW, Douek DC, Price DA, O'Connor DH. Simian immunodeficiency virus SIVmac239Deltanef vaccination elicits different Tat28-35SL8-specific CD8+ T-cell clonotypes compared to a DNA prime/adenovirus type 5 boost regimen in rhesus macaques. J Virol. 2011 Apr; 85(7):3683-9.
Score: 0.088
-
Vogel TU, Friedrich TC, O'Connor DH, Rehrauer W, Dodds EJ, Hickman H, Hildebrand W, Sidney J, Sette A, Hughes A, Horton H, Vielhuber K, Rudersdorf R, De Souza IP, Reynolds MR, Allen TM, Wilson N, Watkins DI. Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence? J Virol. 2002 Nov; 76(22):11623-36.
Score: 0.012